Description

Retatrutide (LY3437943) is a next-generation triple hormone receptor agonist, also referred to as GLP-3, that simultaneously targets GIP, GLP-1, and Glucagon (GCG) receptors. Unlike previous dual-agonists, Retatrutide’s inclusion of the glucagon pathway facilitates an investigation into increased energy expenditure and direct lipid oxidation.

 

Prometheus Labs offers Retatrutide 10mg vials for Canadian researchers with 99%+ HPLC-verified purity. Our batch-specific testing ensures that researchers receive the most stable, high-affinity ligand for metabolic and adipose tissue studies within Canada.

Molecular Profile & Chemical Specifications

Retatrutide is a 39-amino acid modified peptide with a C20 fatty diacid moiety that allows for a prolonged half-life (approx. 6 days) in experimental models.

• Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular Weight: 4731.34 Da
• Sequence: Y-{Aib}-QGTFTSDYSI-{α-Me-Leu}-LDK-{Lys(sidechain)}-AQ-{Aib}-AFIEYLLEGGPSSGAPPPS-NH2
• Purity: ≥99.0% (Verified via HPLC and Mass Spectrometry)
• Target Receptors: GCGR, GIPR, and GLP-1R

Triple Agonist Research Mechanisms

Retatrutide’s multi-pronged approach is designed to study the synergy between appetite suppression and thermogenesis.

1. GIP & GLP-1 Receptor Agonism (Incretin Signaling)

Researchers utilize Retatrutide to study the incretin effect, where GIP and GLP-1 work together to enhance glucose-dependent insulin secretion. In laboratory models, these receptors are studied for their role in delaying gastric emptying and signaling satiety within the central nervous system (CNS).

2. Glucagon (GCG) Pathway & Energy Expenditure

The unique addition of the Glucagon receptor agonist differentiates Retatrutide from compounds like Tirzepatide. This pathway allows for the investigation of:

• Thermogenesis: Potential increases in calorie expenditure even at rest.
• Lipolysis: The breakdown of stored fats into free fatty acids for fuel.
• Liver Fat Reduction: Studies suggest a significant impact on hepatic steatosis models.

Stability & Storage Data

Retatrutide is a complex, modified peptide that requires specific handling to maintain its secondary helical structure.

Condition	Physical State	Stability Period
-80°C (Deep Freeze)	Lyophilized Powder	24+ Months
-20°C (Standard Freezer)	Lyophilized Powder	12 Months
2°C to 8°C (Refrigerator)	Lyophilized Powder	3-6 Months
2°C to 8°C (Refrigerator)	Reconstituted Solution	7-14 Days

Handling Recommendation: Always allow the vial to reach room temperature before reconstitution. Use Bacteriostatic Water for research requiring multi-dose stability. Avoid ultrasonic cleaners or aggressive agitation, as high-frequency vibration can damage the peptide’s structural integrity.

Retatrutide Canada, Research & Compliance FAQ

Q: Is Retatrutide legal to buy in Canada?

A: Retatrutide is not a controlled substance under the Controlled Drugs and Substances Act (Canada). It is legally available for legitimate laboratory research purposes. Prometheus Labs supplies Retatrutide exclusively for non-clinical research use. It is not approved by Health Canada for human therapeutic, diagnostic, or weight loss use.

 

Q: What is GLP-3 and is it the same as Retatrutide?

A: GLP-3 is an informal designation used in the research community to refer to Retatrutide, reflecting its triple receptor agonism of GLP-1, GIP, and Glucagon pathways. The formal compound designation is LY3437943. Prometheus Labs supplies Retatrutide under its correct chemical identity with full HPLC and mass spectrometry verification.

 

Q: How does Retatrutide differ from semaglutide and tirzepatide in research?

A: Semaglutide targets only the GLP-1 receptor. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide adds a third pathway, Glucagon receptor agonism, which introduces thermogenesis and direct lipid oxidation into the research model. This makes Retatrutide the most comprehensive triple-hormone metabolic research compound currently available for Canadian laboratory studies.

 

Q: Does Prometheus Labs provide a Certificate of Analysis for Retatrutide?

A: Yes. Every 10mg vial of Retatrutide is supplied with a batch-specific Certificate of Analysis verified by HPLC and Mass Spectrometry. The COA confirms compound identity, purity at 99%+, and the absence of truncated sequences. The Lab Report is available directly on this product page.

 

Retatrutide Product & Sourcing FAQ

Q: How does Retatrutide differ from Tirzepatide in a research setting?

A: While Tirzepatide is a dual GLP-1/GIP agonist, Retatrutide adds a third receptor, Glucagon. This makes it a primary entity for studying “triple-hormone” synergy, specifically how glucagon-mediated fat burning complements incretin-mediated appetite suppression.

 

Q: What is the purity level of your Retatrutide?

A: Every 10mg vial of Retatrutide from Prometheus Labs is verified to be 99%+ pure. We use HPLC to ensure the absence of truncated sequences and Mass Spectrometry to confirm the correct 39-amino acid molecular mass.